Abstract: The present invention is based, in part, on assays we conducted that revealed compounds that may be used to treat or prevent diseases characterized by an abnormal or undesirable association of one protein with another.

Abstract: Provided are a polymerizable liquid crystal composition, a coating material, a medium, and a polarizing device each produced using a polymerizable liquid crystal compound and a colorant and each capable of producing polarized light suitable for polarizing devices, and also a novel naphtholactam derivative, a novel coumarin derivative, a novel Nile Red derivative, and a novel anthracene derivative each suitable for use as the colorant. Specifically provided are a polymerizable liquid crystal composition containing (A) at least one liquid crystal compound having a polymerizable functional group, (B) at least one colorant, and (C) a polymerization initiator, and a novel naphtholactam derivative of formula (IV?), a novel coumarin derivative of formula (VI?), a novel Nile Red derivative of formula (VII?), and a novel anthracene derivative of formula (VIII?) each suitable for use as the colorant (B).

Abstract: The present invention provides a compound of formula I: a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Abstract: The present invention is based, in part, on assays we conducted that revealed compounds that may be used to treat or prevent diseases characterized by an abnormal or undesirable association of one protein with another.

Abstract: Muscarinic acetylcholine receptor antagonists and methods of using them for the treatment of muscarinic acetylcholine receptor-mediated diseases, such as pulmonary diseases, are provided.

Abstract: An optical filter containing at least one naphtholactam derivative represented by general formula (I), wherein X is oxygen or sulfur; R1, R2, R3, R4, R5, R6, and Y are each hydrogen, halogen, nitro, cyano, aldehyde, carboxyl, hydroxyl, —NRR?, organosilyl, optionally substituted C1-C30 alkyl, optionally substituted C6-C30 aryl, or optionally substituted C7-C30 arylalkyl; and R and R? are each hydrogen, optionally substituted C1-C30 alkyl, or optionally substituted C6-C30 aryl.

Abstract: An imide compound represented by the formula (I): wherein R1 represents a C1-C20 aliphatic hydrocarbon group etc., W1 represents —CO—O— etc., Q1 and Q2 each independently represent a fluorine atom etc., and A represents a group represented by the formula (I-1): wherein A1 represents —CH2—CH2— etc., and a chemically amplified resist composition containing the same.

Abstract: An optical filter containing at least one naphtholactam derivative represented by general formula (I), wherein X is oxygen or sulfur; R1, R2, R3, R4, R5, R6, and Y are each hydrogen, halogen, nitro, cyano, aldehyde, carboxyl, hydroxyl, —NRR?, organosilyl, optionally substituted C1-C30 alkyl, optionally substituted C6-C30 aryl, or optionally substituted C7-C30 arylalkyl; and R and R? are each hydrogen, optionally substituted C1-C30 alkyl, or optionally substituted C6-C30 aryl.

Abstract: Hetero-substituted acetanilide derivatives are disclosed as analgesic agents. The compounds of the invention are useful in methods for treating a disease or condition in a mammal characterized by pain and/or fever.

Abstract: The present invention has for an object novel naphthalene dyes of formula (I) and colorants for keratin fibers, particularly human hair, containing these compounds.

Abstract: The present invention relates to a deuterated polyimide, the backbone of which comprises an alternation between: at least one repeat unit corresponding to the following formula (I): in which: Y represents a single bond or a spacer group; and at least one repeat unit corresponding to the following formula (II): -A1-Z-??(II) in which: A1 represents a perdeuterated aromatic group comprising from 6 to 10 carbon atoms; Z represents a single bond or a group chosen from —O—C6D4-, —CO—C6D4- and —C6D4-. These polyimides are used in particular as materials which are transparent within the region from 2500 to 3500 cm?1, for example in laser devices.

Abstract: A compound of formula (I) wherein A and B are optionally substituted cyclohexenyl or phenyl groups, X is carbonyl or sulfonyl, and Y is 5–7 atoms-linker, is useful as histone deacetylase inhibitors, particularly for inhibiting cell proliferation.

Abstract: The present invention relates to pharmaceutically acceptable compounds, including certain substituted indolinyl and derivatives thereof, 1,2,3,4-tetrahydroquinolinyl and derivatives thereof, 1,2,3,4-tetrahydroisoquinolinyl, benz[cd]indolinyl and 5,6-dihydrophenanthridinyl compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are particularly useful for the treatment or prophylaxis of neurological injury and neurodegenerative disorders.

Abstract: Disclosed are novel naphthostyrils of formula These compounds inhibit cyclin-dependent kinases (CDKs), in particular CDK2. These compounds and their pharmaceutically acceptable salts and esters are anti-proliferative agents useful in the treatment or control of cell proliferative disorders, in particular cancer. Also disclosed are pharmaceutical compositions containing such compounds, methods for the treatment and/or prevention of cancer using such compositions, and intermediates useful in the preparation of the compounds of formula I.

Abstract: Disclosed are novel naphthostyrils of formula 1

Abstract: The invention concerns compounds of formula (I) in which: A forms a tricyclic system of formula A1, A2, A3 or A4; R1 represents a hydrogen atom, an alkyl, hydroxy, alkoxy or oxo group; (R2)m and (R3)m′ are such as defined in the description; n represents an integer such that 0≦n≦3; p represents an integer such as defined in the description; B represents a group (a) or (b). The invention is useful for preparing medicines.

Abstract: A compound of formula (I) for use in the treatment or prevention of mental diseases A is N, CH, C having a double bond or CR5; each of B and Z is independently N, CH or CR1, with the proviso that A is N when B and/or Z is N; R1, R2, R3, R4 and R5 and n are as defined in the specification.

Abstract: 1. WF16616 substance represented by the following structural formula (1) or its pharmaceutically acceptable salt. ##STR1## WF16616 substance exhibits an antimicrobial activity, especially an excellent antifungal activity.

Abstract: The invention relates to a compound selected from these of formula (I): ##STR1## in which R.sub.7, R.sub.8, Y, n and A are as defined in the description, and medicinal product containing the same useful for treating a disorder of the melatoninergic system.

Abstract: A compound of the formula ##STR1## in which A, R.sup.1 and n have the meanings stated in the description are described. The novel compounds are suitable for controlling diseases.

Abstract: A compound of formula (I) and pharmaceutically acceptable salts thereof, where Z is R.sub.3 and X and Y form (a), or X is R.sub.3 and Y and Z form (a) or (b); R.sub.1 and R.sub.2 are independently hydrogen, C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, --CH.sub.2 --C.sub.3-7 cycloalkyl, phenyl (optionally substituted with halogen or C.sub.1-6 alkyl), -thiophenyl (optionally substituted with halogen or C.sub.1-6 alkyl), or C.sub.1-6 alkyl phenyl; R.sub.3 are independently hydrogen, halogen, --O--C.sub.1-6 alkyl or C.sub.1-6 alkyl; R.sub.4 is a valence bond, CH.sub.2 or oxygen; R.sub.5 and R.sub.6 are independently hydrogen, sulfur, --S--C.sub.1-6 alkyl, halogen, CON(R.sub.3).sub.2, --COCF.sub.3, --CO--C.sub.1-6 alkyl, --CO phenyl, oxygen, --CHO, CN except that when Y and Z form (b), R.sub.1 and R.sub.2 are hydrogen or a C.sub.1-6 alkyl and R.sub.3 is hydrogen, then at least one of R.sub.5 and R.sub.6 must be other than hydrogen.

Abstract: A process for preparing a flame retardant bisimide composition which comprises reacting i) diamine with ii) a mixture of ethylenically unsaturated dicarboxylic acid anhydride and a halogenated compound containing aromatic or bicyclo groups and an anhydride groups to form an intermediate bisamic acid composition, the molar ratio of the halogenated compound to the ethylenically unsaturated dicarboxylic acid anhydride being no more than 1:1; and dehydrating the bisamic acid composition to ring close the end groups and form a flame retardant bisimide composition having end groups which contain ethylenically unsaturated carbon-carbon bonds and end groups free of non-benzenoid unsaturation containing halogen atoms and aromatic or bicyclo groups.

Abstract: Novel cytochalasins are the biotransformed products after incubation with a substrate in a culture of the microorganism Kibdelosporangium sp. (Merck Culture Collection MA 6559), ATCC No. 53771. The compounds of the present invention inhibit HIV protease and are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, either as a compound, pharmaceutically acceptable salt, pharmaceutical composition ingredient, whether or not as a prodrug or as a combination with other antivirals, anti-infectives, immunomodulators, antibiotics or vaccines.

Abstract: Compounds of the formula: ##STR1## wherein R.sup.1, R.sup.2 and m are defined in the specification are provided. These compounds are useful as antihypertensive agents.

Abstract: An antiviral agent produced by Hypoxylon fragiforme and having the structure: ##STR1## is described. The product has high activity as an HIV protease enzyme inhibitor and is useful in the treatment of diseases in which control of HIV protease activity is desirable.

Abstract: There is disclosed a method for the treatment of immunoinflammatory conditions, such as allergy, anaphylaxis, asthma, psoriasis, inflammatory bowel disease and inflammation in mammals which comprises administering to a mammal so afflicted an effective amount of a compound having the formula: ##STR1## wherein Z is a group having the formula ##STR2## R.sup.1 and R.sup.2 are each, independently, hydrogen or lower alkyl; R.sup.3 and R.sup.4 are each, independently, hydrogen, alkyl of 1-20 carbon atoms, halo, halo lower alkyl, halo lower alkoxy, lower alkoxy, halo lower alkylsulfonyl, nitro or trifluoromethyl, where at least one of R.sup.3 and R.sup.4 is other than hydrogen;R.sup.5 is hydrogen, lower alkyl or halo;A is --CH.sub.2 --, --O-- or --S--;m is 0-10;n is 1-8;X is hydrogen, fluoro, lower alkyl or aralkyl of 7-12 carbon atoms;or a pharmacologically acceptable salt thereof.

Abstract: 3-Amino-2-cyanoacrylonitrile derivatives of the formula ##STR1## where R is substituted C.sub.1 -C.sub.10 -alkyl, substituted or unsubstituted styryl, substituted or unsubstituted phenyl or aromatic heterocyclyl, are prepared by treating a nitrile in an inert organic diluent at from 0.degree. to +30.degree. C. with a substituted or unsubstituted C.sub.1 -C.sub.6 -alkanol in the presence of a hydrogen halide and reacting the resulting iminoester hydrohalide directly or after isolation with malodinitrile in an inert organic diluent at from 20.degree. to 100.degree. C. in the presence of a base.

Abstract: Process for the preparation of naphthostyril by dissolving 1,8-naphthalimide in an aqueous solution of lithium hydroxide and potassium hydroxide while heating at 40.degree. C. to 80.degree. C., cooling the solution obtained to 14.degree. C. and seeding it at said temperature with a maximum of 1 mol-% of sodium 1,8-naphthalimide per 1 mol of 1,8-naphthalimide used, then adding chlorine bleaching liquor at 10.degree. C. to 20.degree. C., reductively removing excess active chlorine after the reaction has taken place, adjusting the alkaline aqueous solution produced of the alkali-metal salt of the 1-aminonaphthal-ene-8-carboxylic acid formed to a pH of 2.0 by adding acid and isolating the naphthostyril which precipitates in this process.

Abstract: D-2-Alkyl(or phenyl)thio-6-n-alkylergolines or .+-.-2-alkyl(or phenyl)thio-4-dialkylaminotetrahydrobenz[c,d]indoles, dopamine D-1 antagonists.

Abstract: Dyestuffs of the formula ##STR1## wherein R represents hydrogen or optionally substituted alkyl,A represents ##STR2## wherein R.sup.1 represents hydrogen, optionally substituted alkyl or cycloalkyl andR.sup.2 represents optionally substituted alkyl which can close a ring to ring B, aralkyl or aryl orR.sup.1 and R.sup.2, together with the N atom, form a ring,D and E represent hydrogen, optionally substituted alkyl or alkenyl and D additionally represents aryl, aralkyl, aralkenyl or a heterocyclic radical, or D and E, together with the C atom, form a ring andAn.sup.- represents an anion,are used for pulp-coloring paper and dyeing cationically dyeable fibres.

Abstract: There is described a novel process for producing 1,8-naphtholactam compounds of the formula I ##STR1## wherein the symbols R, A and B have the meanings defined in claim 1. This process comprises reacting a 1,8-naphtholactone compound of the formula II ##STR2## in an aqueous medium, with an amine of the formula IIINH.sub.2 --R (III),optionally in the presence of bisulfite. The naphtholactam compounds of the formula I are obtained with a high degree of purity and with a yield of over 90%.

Abstract: Benzil-di[.beta.-(di-.beta.-methallylisocyanuryl)ethyl]ketal of the following structural formula: ##STR1## and other novel benzil ketal derivatives. The novel benzil ketal derivatives are characterized by having a structure in which an isocyanuryl-containing group is bonded to each of the two oxygen atoms of ketal. Because these compounds have a high decomposition or sublimation temperature and ability to initiate photopolymerization, they are useful as photopolymerization initiators in the production of photopolymerizable shaped articles from a molten blend of a photopolymerizable thermoplastic polymer composition.

Abstract: Herein are disclosed compounds of the formula ##STR1## in which R.sup.1 is hydrogen, lower alkyl or --(CH.sub.2).sub.m --NR.sup.4 R.sup.5 wherein m is an integer from 2 to 6 and R.sup.4 and R.sup.5 each is hydrogen or lower alkyl; R.sup.2 is hydrogen, bromo or chloro; and R.sup.3 is hydrogen or halo; with the requirement that when R.sup.2 is bromo or chloro, then R.sup.3 is bromo or chloro or a therapeutically acceptable salt thereof. The compounds inhibit lens aldose reductase in a diabetic mammal.